Lupin, a global pharmaceutical company, has appointed Abdelaziz Toumi as the Chief Executive Officer (CEO) of its API (Active Pharmaceutical Ingredient) CDMO (Contract Development and Manufacturing Organization) subsidiary. The appointment is effective immediately.
Toumi brings over 25 years of experience in the pharmaceutical industry, with a strong background in API development, manufacturing, and commercialization. He has held various leadership positions in companies such as Novartis, Roche, and most recently, as the Head of API Manufacturing at Lonza.
As the CEO of Lupin’s API CDMO subsidiary, Toumi will be responsible for leading the company’s API development and manufacturing capabilities, including the production of complex and highly potent APIs. He will also oversee the commercialization of these APIs, working closely with Lupin’s global customers and partners.
Toumi’s appointment is seen as a strategic move by Lupin to strengthen its API capabilities and expand its presence in the CDMO market. The company has been investing heavily in its API development and manufacturing capabilities, and Toumi’s expertise will help drive this growth.
Lupin’s API CDMO subsidiary offers a range of services, including API development, manufacturing, and packaging, as well as regulatory support and quality control. The company serves a diverse range of customers, including pharmaceutical companies, biotechnology firms, and research institutions.
In a statement, Lupin’s Managing Director, Vinita Gupta, welcomed Toumi to the company and expressed her confidence in his ability to lead the API CDMO subsidiary to success. “Abdelaziz brings a wealth of experience and expertise to Lupin, and we are excited to have him on board,” she said. “His leadership will be instrumental in driving the growth and success of our API CDMO business.”
Toumi’s appointment is seen as a significant development in the pharmaceutical industry, as it highlights the growing importance of API development and manufacturing capabilities. The appointment also underscores Lupin’s commitment to investing in its API business and expanding its presence in the CDMO market.